Due to these survival benefits, IDH1/2 mutations are not only valuable prognostic biomarkers but are also being investigated as potential therapeutic targets, with IDH inhibitors currently in clinical trials aiming to improve survival for this subset of glioma patients [50]. The gene discussed is IDH2; the disease is central nervous system cancer.